These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11363700)

  • 1. NeXstar Pharmaceuticals lauches DaunoXome.
    J Int Assoc Physicians AIDS Care; 1996 Jun; 2(6):52. PubMed ID: 11363700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA approves DaunoXome as first-line therapy for Kaposi's sarcoma. Food and Drug Administration.
    J Int Assoc Physicians AIDS Care; 1996 May; 2(5):50-1. PubMed ID: 11363534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DaunoXome offers KS treatment alternative.
    AIDS Alert; 1996 Jun; 11(6):67-8. PubMed ID: 11363544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kaposi's sarcoma: DaunoXome approved.
    AIDS Treat News; 1996 May; (no 246):3-4. PubMed ID: 11363485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.
    Gill PS; Wernz J; Scadden DT; Cohen P; Mukwaya GM; von Roenn JH; Jacobs M; Kempin S; Silverberg I; Gonzales G; Rarick MU; Myers AM; Shepherd F; Sawka C; Pike MC; Ross ME
    J Clin Oncol; 1996 Aug; 14(8):2353-64. PubMed ID: 8708728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.
    Fassas A; Buffels R; Anagnostopoulos A; Gacos E; Vadikolia C; Haloudis P; Kaloyannidis P
    Br J Haematol; 2002 Feb; 116(2):308-15. PubMed ID: 11841431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Administration of liposomal preparation of DaunoXome for breast cancer in patients with poor prognosis].
    Darskaia EI; Zubarovskaia LS; Afanas'ev BV
    Vopr Onkol; 1999; 45(4):440-4. PubMed ID: 10532108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal daunorubicin: new preparation. Kaposi's sarcoma: occasional remission.
    Prescrire Int; 1998 Apr; 7(34):41-2. PubMed ID: 10183380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DaunoXome approved.
    AIDS Patient Care STDS; 1996 Aug; 10(4):263. PubMed ID: 11361607
    [No Abstract]   [Full Text] [Related]  

  • 10. Paclitaxel for treating KS.
    Proj Inf Perspect; 1997 Nov; (23):15. PubMed ID: 11365372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extravasation of liposomal daunorubicin in patients with AIDS-associated Kaposi's sarcoma: a report of four cases.
    Cabriales S; Bresnahan J; Testa D; Espina BM; Scadden DT; Ross M; Gill PS
    Oncol Nurs Forum; 1998; 25(1):67-70. PubMed ID: 9460774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DOXIL approved by FDA.
    AIDS Patient Care; 1995 Dec; 9(6):306. PubMed ID: 11361446
    [No Abstract]   [Full Text] [Related]  

  • 13. Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.
    Löfgren C; Lehmann S; Jönsson-Videsäter K; Möllgård L; Linder O; Tidefelt U; Hassan M; Paul C
    Ther Drug Monit; 2007 Oct; 29(5):626-31. PubMed ID: 17898654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA approves KS drug. Food and Drug Administration. Florida Department of Health and Rehabilitation Services.
    AIDS Alert; 1996 Jan; 11(1):11-2. PubMed ID: 11363227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia.
    Piccaluga PP; Visani G; Martinelli G; Isidori A; Malagola M; Rondoni M; Baccarani M; Tura S
    Leukemia; 2002 Sep; 16(9):1880-1. PubMed ID: 12200714
    [No Abstract]   [Full Text] [Related]  

  • 16. Liposomal daunorubicin marketed for HIV-related Kaposi's sarcoma.
    Am J Health Syst Pharm; 1996 Jul; 53(13):1500, 1505. PubMed ID: 8809269
    [No Abstract]   [Full Text] [Related]  

  • 17. A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer.
    O'Byrne KJ; Thomas AL; Sharma RA; DeCatris M; Shields F; Beare S; Steward WP
    Br J Cancer; 2002 Jul; 87(1):15-20. PubMed ID: 12085249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes.
    Yeo W; Chan KK; Mukwaya G; Ross M; Leung WT; Ho S; Chan AT; Johnson PJ
    Cancer Chemother Pharmacol; 1999; 44(2):124-30. PubMed ID: 10412946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia.
    Russo D; Piccaluga PP; Michieli M; Michelutti T; Visani G; Gugliotta L; Bonini A; Pierri I; Gobbi M; Tiribelli M; Fanin R; Piccolrovazzi S; Baccarani M
    Ann Hematol; 2002 Aug; 81(8):462-6. PubMed ID: 12224004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin.
    Zucchetti M; Boiardi A; Silvani A; Parisi I; Piccolrovazzi S; D'Incalci M
    Cancer Chemother Pharmacol; 1999; 44(2):173-6. PubMed ID: 10412954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.